IRCT20230128057251N1招募中3 期
Clinical evaluation the effect of Xylapi ointment and lidocaine spray on the patient's satisfaction, stress, cooperation and pain level in spinal anesthesia for cesarean section and comparing it with the control group
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 258
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 50 years（—）
- 性别
- Female
入选标准
- •Pregnant women referred to Bharlo Hospital with a gestational age of more than 37 weeks who are candidates for elective cesarean section
排除标准
- •Gestational age below 37 weeks
- •Pregnant women who are candidates for emergency cesarean section
- •Pregnant women with chronic hypertension and diabetes
- •History of allergy to lidocaine
- •History of addiction and contraindications for spinal anesthesia
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)End-Stage Kidney DiseaseMedDRA version: 21.1Level: LLTClassification code: 10014646Term: End stage renal disease (ESRD) Class: 10038359CTIS2024-513562-19-00Iperboreal Pharma S.r.l.170
进行中（未招募）
不适用
Safety and efficacy of a new solution, XyloCore, for peritoneal dialysisChronic kidney diseaseISRCTN16169961Sintesi Research170
招募中
不适用
Comparison of the effectiveness of Xyla-p and cold needle cream on pain intensityIRCT20131113015393N7Sabzevar University of Medical Sciences80
进行中（未招募）
1 期
A Study to Evaluate the EffIcacy and Safety of XyloCore, a low-glucose solution for peritoneal dialysisEnd-Stage Renal Disease (ESRD)MedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-004183-21-DEIperboreal Pharma Srl170
进行中（未招募）
1 期
A Study to Evaluate the EffIcacy and Safety of XyloCore, a low-glucose solution for peritoneal dialysisEnd-Stage Renal Disease (ESRD)MedDRA version: 21.0Level: PTClassification code 10077512Term: End stage renal diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-004183-21-DKIperboreal Pharma Srl170